MBRX
vs
S&P 500
MBRX
S&P 500
Over the past 12 months, MBRX has underperformed S&P 500, delivering a return of -91% compared to the S&P 500's +14% growth.
Stocks Performance
MBRX vs S&P 500
Performance Gap
MBRX vs S&P 500
Performance By Year
MBRX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Moleculin Biotech Inc
Glance View
Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which engages in the development of treatments for highly resistant cancers and viruses. The company is headquartered in Houston, Texas and currently employs 13 full-time employees. The company went IPO on 2016-06-02. The firm has a pipeline of clinical programs for the treatment of highly resistant cancers and viruses. The company has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066 Portfolio (including lead drug candidates WP1066 and WP1220) represents a class of agents capable of hitting multiple targets, including the activated form of a key oncogenic transcription factor, STAT3. WP1066 is its flagship Immune/Transcription Modulator. An analog of WP1066, referred to as WP1220, is related to the use of the molecule in the topical treatment of psoriasis. The firm's WP1122 Portfolio and similar molecules focused on inhibitors of glycolysis and glycosylation.
